A new and promising treatment for diphtheria developed by MassBiologics of UMass Medical School could save lives each year in developing regions of the globe in turmoil where the disease is remerging, such as Yemen and Myanmar, but researchers need $1 to $2 million to bring it to clinical trial, according to a Dec. 20 report on WBUR.
New research by UMass Medical School scientist Douglas T. Golenbock, MD, and colleagues at the University of Bonn in Germany provides a link between innate immune-activated inflammation and Alzheimer’s disease that possibly explains how the disease spreads through the brain.
Thoru Pederson, PhD, was one of 67 scientists named a 2017 fellow of the American Society for Cell Biology in recognition of meritorious efforts to advance cell biology and its applications and for service to the society.
The Massachusetts Medical Device Development Center, a collaboration of UMass Medical School and UMass Lowell, has named the winners of its 2017 Medical Device Innovation competition.
Guangping Gao, PhD, a global leader in the field of adeno-associated virus gene therapy, has been named a 2017 fellow by the National Academy of Inventors.
In this Women in Science video, Clare M. Smith, PhD, a postdoc in the Sassetti lab, talks about her research into the genetic basis for susceptibility to the bacterium Mycobacterium tuberculosis.
Stephenie Lemon, PhD, is a principal investigator on an $8.75 million grant from the National Institutes of Health National Center for Advancing Translational Sciences to demonstrate the feasibility of community–academic partnerships that will translate into reductions in health disparities for vulnerable patients facing any disease.
A study by Craig J. Ceol, PhD, has revealed that a protein called GDF6, active during early embryo development, plays a primary role in metastatic melanoma. The study was published in the Journal of Clinical Investigation.
Celia A. Schiffer, PhD, is taking part in a $5.8 million NIH-funded collaboration led by EpiVax, Inc. to develop a protective vaccine against avian flu.
Jim Glasheen, PhD, a prominent venture capitalist in the biopharmaceutical, medical technology and patient-centered health fields, will join UMass Medical School on Dec. 4 as the executive vice chancellor for innovation & business development.